Living Cell Technologies - Latest News [Page 1]

LCT collaborates to develop novel neurological treatments

Monday, 29 September 2014, 5:15 pm | Living Cell Technologies

Living Cell Technologies Limited has formed a collaboration with the Centre for Brain Research (CBR). The research collaboration will identify additional neurodegenerative disease targets for clinical studies of LCT’s lead product NTCELL®. More >>

LCT Appoints Scientific Advisors

Tuesday, 23 September 2014, 1:23 pm | Living Cell Technologies

Living Cell Technologies Limited (LCT) has appointed three high-level scientific advisors to review and support its work as NTCELL progresses towards commercialisation. The appointments are Professors Anne Young from Harvard, Roger Barker from Cambridge ... More >>

Successful second implant of NTCELL for Parkinson’s

Monday, 18 August 2014, 3:34 pm | Living Cell Technologies

18 August 2014 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL® ... More >>

Dr Ken Taylor appointed Chief Executive

Tuesday, 8 July 2014, 1:19 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that Dr Ken Taylor has been appointed Chief Executive. Ken was appointed NTCELL Program Director in February and became Acting Chief Executive in April. He has been successful resuming patient recruitment ... More >>

LCT Parkinson’s trial resumes patient recruitment

Monday, 23 June 2014, 1:00 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. More >>

Withdrawal of NTCELL pre-clinical study

Thursday, 20 February 2014, 4:00 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that it is withdrawing the publication of the pre-clinical study of the effects of NTCELL in a rat model of Parkinson’s disease. The data will also be withdrawn from all regulatory documentation. More >>

NTCELL clinical trial: Recruitment of further patients

Monday, 25 November 2013, 1:35 pm | Living Cell Technologies

Living Cell Technologies Limited today announced that the independent data safety monitoring board (DSMB) has reviewed the safety data from the initial patient in the Phase I/IIa clinical trial of NTCELL and advised that implants for the additional ... More >>

Living Cell Technologies a finalist

Thursday, 28 March 2013, 12:05 pm | Living Cell Technologies

Living Cell Technologies a finalist in 2013 New Zealand Hi-Tech Awards Auckland, 28 March 2013 – Living Cell Technologies was last night announced as a finalist in the 2013 New Zealand Hi-Tech Awards. The company is a finalist in the Cisco Hi-Tech ... More >>

Living Cell Technologies Awarded NZBIO Company of the Year

Wednesday, 20 March 2013, 11:09 am | Living Cell Technologies

Living Cell Technologies Limited Company Announcement Living Cell Technologies Awarded NZBIO Company of the Year More >>

LCT appoints Chief Science and Medical Officer

Monday, 10 December 2012, 11:46 am | Living Cell Technologies

10 December, 2012 Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the appointment of Dr Paul Tan to the position of Chief Science and Medical Officer (CSMO). More >>

LCT starts DIABECELL® Phase IIb trial

Thursday, 22 November 2012, 1:33 pm | Living Cell Technologies

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has begun patient recruitment in Argentina for a Phase IIb trial of DIABECELL®. More >>

Strong interim result in Phase I/IIa DIABECELL® trial

Thursday, 22 November 2012, 1:21 pm | Living Cell Technologies

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the results of an interim analysis of its Argentinian Phase I/IIa clinical trial for DIABECELL®, a breakthrough treatment ... More >>

LCT CEO Dr Andrea Grant appointed Managing Director

Friday, 16 November 2012, 12:43 pm | Living Cell Technologies

16 November 2012: Sydney, Australia and Auckland, New Zealand – Roy Austin, chairman of Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), is pleased to announce the appointment of Dr Andrea Grant to the board as Managing Director. Dr Grant joined ... More >>

Ethical approval for LCT’s NTCELL® Phase I trial

Friday, 16 November 2012, 12:02 pm | Living Cell Technologies

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase ... More >>

Otsuka commits $A25 million to JV with LCT

Wednesday, 19 October 2011, 2:29 pm | Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has agreed to establish a 50/50 joint venture company DIATRANZ OTSUKA LIMITED with Otsuka Pharmaceutical Factory, Inc. (“Otsuka”) to accelerate the commercialisation of LCT’s DIABECELL®, ... More >>

Cost of treating Type 1 diabetes could double to $340bn

Wednesday, 19 October 2011, 12:28 pm | Living Cell Technologies

The cost of treating Type 1 diabetes for Australia is a massive $170bn – and the bill could double. Diabetes is the world’s fastest growing chronic disease affecting 220 million people worldwide. In Australia, it is the sixth leading cause of death ... More >>

World Leading Treatment for Diabetes Gathers Pace

Monday, 22 August 2011, 1:40 pm | Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant to treat diabetes, has implanted the first two patients taking part in a Phase II DIABECELL® clinical trial in Buenos Aires, Argentina. More >>

LCT Enrols First Patients in DIABECELL® Argentina Trial

Monday, 27 June 2011, 1:42 pm | Living Cell Technologies

• Enrolment of first two patients signifies the commencement of the Phase II clinical trial, ahead of schedule • Pre-transplant patient monitoring initiated • First DIABECELL transplants at 5,000 IEQ/kg scheduled for August 2011 More >>

Living Cell Technologies Founder wins Prestigious Award

Thursday, 10 March 2011, 3:12 pm | Living Cell Technologies

10 March 2011: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that Medical Director and ... More >>

LCT Receives Funds from Pharmaceutical Investor

Wednesday, 9 March 2011, 1:00 pm | Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, confirmed today the receipt of A$1.7 million from Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK) in ... More >>

 

 

InfoPages Links

 
 
 
 
 

LATEST HEADLINES

 
 
 
InfoPages
Search Scoop  
 
 
Powered by Vodafone
NZ independent news